Our Board of Directors consists of carefully appointed industry leaders who are capable of navigating a flagship company through the unchartered waters of novel science.
Steven Gillis, PhD Chairman
Steven Gillis has been a managing director at ARCH Venture Partners since 2005. Dr. Gillis was a founder and director of Corixa Corporation and served as the company’s Chief Executive Officer since inception and as its chairman since January of 1999. GlaxoSmithKline acquired Corixa Corporation in July of 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corporation. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis was interim Chief Executive officer of Immunex Corporation following its majority purchase by American Cyanamid Company. Dr. Gillis remained on the Board of Directors of Immunex until 1997. Immunex was acquired by Amgen in 2002. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978. He currently serves as a director or Chairman of multiple private and public biotechnology companies in the United States.
Brian Daniels, MD Non-Executive Director
Brian has twenty years of experience in clinical development, medical affairs, and commercialization. Amongst Brian’s accomplishments was directing the drug development efforts at Bristol-Myers Squibb Company (BMS). His efforts led to the registration of numerous innovative medicines for the treatment of cancer, HIV, viral hepatitis, depression, rheumatoid arthritis, diabetes, cardiovascular disorders, and rare genetic disorders. More than ten of these medicines achieved greater than $1billion annual sales. He was also responsible for communicating the value of these medicines to payers and ensuring their safe and appropriate use.
Through July 2014, Dr. Brian Daniels served as Senior Vice President, Global Development and Medical Affairs, and a member of the Senior Management Team, at BMS. Brian’s contributions at BMS were exceptional and, as a consequence, he has earned an unparalleled reputation across the industry. He also has prior Development experience at both Merck and Genentech.
Brian’s areas of expertise include all aspects of R&D in biopharma (from Research to Development organization, process and portfolio topics). He also has deep expertise in Medical Affairs and clinical operations.
Brian has built a network of relationships within both biopharma and the VC community, he has a track record of developing and launching new drugs across both primary and specialty care (he led one of the most productive Development organizations across the entire biopharma industry in the last decade), and he is highly recognized among the scientific community.
In addition to his role as a Senior Advisor with BCG, Brian now serves as a Venture Partner at 5am Ventures in Menlo Park, California and volunteers at The Gladstone Institutes at the University of California in San Francisco as a translational partner.
He is a member of the Board for Novo Nordisk A/S.
Lawrence Gozlan Non-Executive Director
Lawrence Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. With 15 years of experience in investing and banking, Lawrence has expertise in all areas of investment management and deep roots in the scientific and biotech communities.
Prior to Scientia Lawrence was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over AU$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained corporate finance experience advising life science companies at Deloitte.
Lawrence currently serves as a Director on the Board of Prana Biotechnology (NASDAQ: PRAN). He holds a Bachelor of Science with Honours in immunology from the University of Melbourne.
Michael Sistenich Non-Executive Director
Michael Sistenich has over 18 years’ experience in senior leadership roles in the life sciences industry as an investor, advisor, and investment banker. Most recently, Michael served as Interim Chief Executive Officer of Nohla Therapeutics, Inc., during which time he successfully spearheaded its startup and guided its transformational Series A financing in November 2016. He was the Director and Head of life sciences investment banking at Bell Potter Securities from June 2014 until he joined Nohla. Prior to Bell Potter, he was the Founder and Senior Portfolio manager of the Meditor Cobra fund, a EUR 500mn Healthcare Hedge fund based in London. From 1997 to 2003, Michael served as Director and Global Head of Healthcare at DWS Investments, Deutsche Bank, overseeing EUR 6bn of direct investments in the public and private markets. Michael holds an M.Sc in Biochemistry from the University of Oxford, UK.
Kathleen Fanning President and Chief Executive Officer
Kathleen Fanning is the President and Chief Executive Officer of Nohla Therapeutics. Ms. Fanning has over 30 years of industry experience holding previous leadership roles in both public and private biopharmaceutical companies, most recently serving as Chief Operating Officer at VentiRx Pharmaceuticals. During her tenure at VentiRx, she led strategic planning activities and corporate and business development. She played an instrumental role in the strategic collaboration between VentiRx and Celgene Corporation. Prior to joining VentiRx, Ms. Fanning held senior leadership roles at Cell Therapeutics Inc., as Vice President of Acquisitions and Vice President of Sales and Marketing, with responsibilities that included building and managing the company’s first global sales and marketing organization. She also served as Senior Director of Sales and Marketing at CellPro, Inc. and spent 13 years at Zeneca Pharmaceuticals (now AstraZeneca), with increasing roles of responsibility including Director of Marketing for Oncology Products, where she led the successful U.S. launch of Arimidex®. Ms. Fanning received her B.A. in Zoology from Miami University in Oxford, Ohio.